Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
A phase 3 trial of Alpelisib, Trastuzumab and Pertuzumab in HER2-positive breast cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation is a phase 3 interventional study registered as NCT04208178 by Novartis Pharmaceuticals, with 19 participants enrolled, started 2020-07-16 and due to reach its primary completion in 2027-02-26. Interventions recorded: Alpelisib, Alpelisib matching Placebo, Trastuzumab and Pertuzumab.
Similar pages
not linked directly; found by shared links- TrialClinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), HER2-positive breast cancer and the tag pipeline.
- TrialAlpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Shares Alpelisib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Shares Alpelisib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Shares Alpelisib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Shares Alpelisib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialStudy of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialA Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, HER2-positive breast cancer and the tag pipeline.